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Abstract
Antiproliferative and antibacterial activities of nine glutarimide derivatives (1–9) were reported.
Cytotoxicity of compounds was tested toward three human cancer cell lines, HeLa, K562 and
MDA-MB-453 by MTT assay. Compound 7 (2-benzyl-2-azaspiro[5.11]heptadecane-1,3,7-trione),
containing 12-membered ketone ring, was found to be the most potent toward all tested cell
lines (IC50¼ 9–27 mM). Preliminary screening of antibacterial activity by a disk diffusion method
showed that Gram-positive bacteria were more susceptible to the tested compounds
than Gram-negative bacteria. Minimum inhibitory concentration (MIC) determined by a broth
microdilution method confirmed that compounds 1, 2, 4, 6–8 and 9 inhibited the growth of all
tested Gram-positive and some of the Gram-negative bacteria. The best antibacterial potential
was achieved with compound 9 (ethyl 4-(1-benzyl-2,6-dioxopiperidin-3-yl)butanoate) against
Bacillus cereus (MIC 0.625mg/mL; 1.97 103mol/L). Distinction between more and less active/
inactive compounds was assessed from the pharmacophoric patterns obtained by molecular
interaction fields.
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Introduction
Both naturally occurring and synthetic cyclic imides, especially
five- and six-membered systems, are an important group of
bioactive molecules. They exhibit widespread pharmacological
effects, including antitumor1–4, anti-inflammatory5, immunomo-
dulatory, antiangiogenic and anxiolytic6–8.
Isolation and examination of pharmacologically active natural
glutarimides started in 1960s. Initially, cycloheximide9 and
streptimidone10–12 were examined as antibiotics, but later it
was found that they acted as very potent cytotoxic agents13,14.
The structurally related streptimidone derivative, 9-methylstrepti-
midone, exerts a significant inhibitory activity toward nuclear
factor-kB (N-kB)15. N-kB is involved in cancer and inflamma-
tions. Alkaloids (+)-sesbanimide A and ()-sesbanimide B were
isolated from the seeds of the leguminous plant Sesbania
drummondii1,16. Ethanol extracts of S. drummondii seeds
showed significant inhibitory activity against P388 murine
leukemia model in mice (in vivo)17–19. Structurally related natural
product lactimidomycin (LTM), 12-membered unsaturated
macrolide antibiotic that comprise biosynthetically rare glutar-
imide side chain, produced by Streptomyces amphibiosporus
R310-104 (ATCC 53964), display strong cytotoxicity against a
number of human tumor cell lines in vitro, in vivo antitumor
activity in mice model and potent antifungal activity2.
In 1990s it was discovered that thalidomide, a well-known
synthetic glutarimide derivative, has anti-inflammatory and
antiangiogenic properties. It was approved as a drug for the
treatment of certain cancers (newly diagnosed multiple myeloma)
and for complication arised from leprosy. Later on, analogs of
thalidomide with increased potency, 3-amino-thalidomid (poma-
lidomid, Pomalyst) and a-(3-aminophthalimido) glutarimide
(lenalidomid, Revlimid) have been developed20,21. Lenalidomid
has been used for the treatment of multiple myeloma, while
pomalidomid has been recently approved by FDA for the
treatment of relapsed and refractory multiple myeloma22.
Some estrone derivatives with the D-ring replaced with the
glutarimide moiety showed potent inhibition of steroid sulfatase,
an enzyme involved in the pathway of the development of
hormone-dependent breast tumors23; while aminoglutethimide,
the non-steroidal aromatase inhibitor, is in use for the treatment of
hormone-sensitive metastatic breast cancer24,25. In the past
decade, antitumor activity in vitro of mitonafide26, amonafide27
and naphthalimide28,29 derivatives was intensively examined.
Upon detail analysis of bioactive compounds that comprise
glutarimide moiety in their structure, as is briefly outlined in
previous paragraphs, we concluded that data on antiproliferative
and on antibacterial activity of compounds 1–9 (Figure 1) cannot
be found in literature. Those compounds have been prepared in our
group to demonstrate novel synthetic approach of glutarimide ring
closure reaction30. All compounds have a common N-substituted
glutarimide moiety in their structure, and bear structurally diverse
substituents in positions 3 and/or 4 of glutarimide ring. We have
tested antiproliferative and antibacterial activity of compounds
1–9 in vitro, and hereby report on the results obtained.
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Methods
Antiproliferative activity
Stock solutions of investigated compounds were prepared in
a nutrient medium (RPMI-1640) supplemented with 3 mM
L-glutamine, 100mg/mL streptomycin, 100 IU/mL penicillin,
10% heat inactivated fetal bovine serum (FBS) and 25 mM
Hepes, adjusted to pH 7.2 by bicarbonate solution. RPMI-1640,
FBS, Hepes and L-glutamine were products of Sigma Chemical
Co., St. Louis, MO. Human cervix adenocarcinoma HeLa, breast
carcinoma MDA-MB-453 and normal lung fibroblast MRC-5
cells were cultured as monolayers in the nutrient medium, while
human myelogenous leukemia K562 cells were maintained as
suspension culture. The cells were grown at 37 C in 5% CO2 and
humidified air atmosphere.
HeLa (2000 cells per well), MDA-MB-453 (3000 c/w) and
MRC-5 (5000 c/w) cells were seeded into 96-well microtiter
plates and 20 h later, after the cell adherence, five different
concentrations of investigated compounds were added to the
wells. Final concentrations were in the range from 200 to
12.5mM. Only nutrient medium was added to the cells in the
control wells. Investigated compound was added to a suspension
of leukemia K562 cells (5000 cells/ well) 2 h after cell seeding,
in the same final concentrations applied to HeLa, MDA-MB-453
and MRC-5 cells. All experiments were done in triplicate.
Nutrient medium with corresponding concentrations of com-
pound, but void of cells, was used as blank.
Cell survival was determined by MTT test according to the
method of Mosmann and modified by Ohno and Abe, 72 h after
addition of the compounds31,32. Briefly, 20 mL of MTT solution
(5 mg/mL in phosphate buffered saline) was added to each well.
Samples were incubated for further 4 h at 37 C in humidified
atmosphere with 5% CO2. Then, 100mL of 10% SDS was added to
the wells. Absorbance was measured at 570 nm the next day.
To achieve cell survival (S%), absorbance at 570 nm of a sample
with cells grown in the presence of various concentrations of
compounds tested was divided with absorbance of control sample
(the absorbance of cells grown in nutrient medium only).
Absorbance of blank was always subtracted from absorbance of
a corresponding sample with cells. All experimentally obtained
IC50 data were means of three measurements done in triplicate.
The antibacterial activity testing
The antibacterial activity of compounds 1, 2, 4–8 and 9 was
determined against four Gram-positive (Staphylococcus aureus,
Enterococcus faecalis, Bacillus cereus, Listeria monocytogenes)
and seven Gram-negative bacterial species [Pseudomonas
aeruginosa, Escherichia coli, Salmonella enteritidis, Proteus
hauseri, Shigella sonnei, Yersinia enterocolitica, E. coli
(O157:H7)]. Selected bacterial strains originated from ATCC
(American Type Culture Collection, Rockville, MD). These
microorganisms were chosen for the bioassay as the well-known
food spoilage and pathogenic bacteria. Each species was main-
tained on Mueller–Hinton agar (MHA), which was also used to
confirm the absence of contamination and the validity of the
inocula. Before testing, each species was recovered by sub-
culturing in Mueller–Hinton broth (MHB), aerobically, for 24 h,
at 37 C. Working concentrations of approximately 105–106 cfu/
mL, used for antibacterial activity assays, were prepared by
proper dilution of culture in microbiological medium.
Compounds were dissolved in DMSO (2%) to prepare stock
solutions at a concentration of 40 mg/mL, sterilized by filtration
through a 0.22-mm membrane filter (Sartorius AG – Go¨ttingen,
Germany) according to Tepe et al. and further diluted in MHB to
a working solutions. DMSO was chosen as a non-toxic solvent33.
Figure 1. Structures of glutarimide deriva-
tives 1–9.
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Disk diffusion assay was performed using a slightly modified
CLSI34. Each bacterial culture (approximately 105–106 cfu/mL)
was added (0.1 mL) to Petri dishes (90 mm) containing MHA
(20 mL). Three sterile blank paper disks (6 mm in diameter,
Susceptibility Test Discs, SD 067-5CT, HiMedia, Mumbai, India)
were placed on the surface of each agar plate and inoculated with
10mL of the compound (20 mg/mL). After 2 h at 25 C, the plates
were incubated aerobically, for 24 h at 37 C. After incubation
period, inhibition zone (mm) was measured including the initial
diameter of the disk. Tests were performed in triplicate and the
results were analyzed for statistical significance. The plates with
MHA were sterility controls. Negative controls were disks
impregnated with DMSO. As positive controls disks (Sigma-
Aldrich GmbH, Steinheim, Germany) with gentamicin (30 mg)
and tetracycline (30mg) were used.
Broth microdilution method was employed to determine
minimum inhibitory concentrations (MICs)34,35. Concentrations
of compound ranged from 10.0 to 0.048 mg/mL. Test bacterial
culture (50mL) in a MHB was added to the wells of a sterile 96-
well microtiter plate (Sarstedt, Numbrecht, Germany) already
containing 50 mL of twofold serially diluted compound in MHB.
The final volume in each well was 100mL. The microplates were
prepared in triplicate and incubated aerobically, for 24 h at
37 C. Wells with MHB was used as a sterility control, while
negative controls were wells with tested compound in 50mL of
MHB, but void of bacteria. Positive controls were wells with a
bacterial suspension in 50 mL of MHB and wells with a bacterial
suspension in a MHB with DMSO, in amounts corresponding to
the highest quantity present in the broth microdilution assay (to
prove that DMSO had no inhibition effect on the bacterial
growth). A microplate shaker (Lab Companion, VM-96B, Seoul,
South Korea) was used for mixing the content of each well at
900 rpm for 1 min prior to incubation in the cultivation
conditions described above. To indicate cellular respiration
2,3,5-triphenyltetrazolium chloride (TTC) (Aldrich Chemical
Company Inc., Sigma-Aldrich, St. Louis, MO) was added to the
culture medium. The final concentration of TTC after inocula-
tion was 0.05%. Viable microorganisms enzymatically reduced
white TTC to a pink TPF (1,3,5-triphenylformazan). The MIC
was defined as the lowest sample concentration that prevented
this change and exhibited complete inhibition of bacterial
growth.
All measurements were done in triplicate and data were
expressed as mean ± standard deviation. The experimental data
were subjected to an one-way analysis of variance (ANOVA) and
Fisher’s LSD was calculated to detect significant difference
(p 0.05) between the mean values.
Molecular modeling
Initial 3D structures of compounds 1–9 were generated from
SMILES notation in CORINA assuming R stereochemistry for all
stereogenic centers, except for C2 of the phenethyl moiety of
compound 636,37. The S stereochemistry was ascribed to this
stereogenic center, on the ground of experimental data30. Initial
structures were imported in VegaZZ38. Up to 20 conformations,
representing local energy minima, were obtained by conform-
ational search on the molecular mechanics level (MMFF94s force
field), using Boltzmann jump algorithm in AMMP39,40. Each
conformation of each compound was minimized by the semi-
empirical molecular orbital PM6 method, using implicit solvation
in water (COSMO) to root mean square gradient of 0.01; by
MOPAC201241,42. Conformation of each compound that had the
lowest heat of formation (implying the most stable one) was
chosen for further modeling. 3D-dependent whole-molecular
properties of compounds, surface area, polar surface area, apolar
surface area, volume and virtual log P, were calculated in
VegaZZ, using 1.4 A˚ probe43. Molecular interaction fields (MIF)
around molecules were calculated by a GRID method, as applied
in Pentacle program, using grid resolution of 0.4 A˚44. Hydrogen-
bond donor (N1), hydrogen-bond acceptor (O), hydrophobic
(DRY) and shape (TIP) probes were used. AMANDA algorithm
were used for the extraction of hot spots (nodes) from the obtained
MIFs (discretization); the distances and relative position of the
nodes were described by maximum auto- and cross-correlation
(MACC2) (encoding). For more exhaustive description of
applied methodology see original reference45. Auto- and cross-
correlograms, obtained by the Pentacle program are depicted
in matrix-like representation, named as heatmap. Values of
variables are color-coded from red (low value) to blue (high
value). For color code in heatmap, depicted in Figure 3, see
on-line version of the article. Correlograms encode molecular
descriptors grounded on two-point pharmacophoric pattern,
which represent the local minima of two probes (nodes) around
molecule, including distance between those nodes. All blocks of
correlograms (DRY-DRY, O-O, N1-N1, TIP-TIP, DRY-O, DRY-
N1, DRY-TIP, O-N1, O-TIP, N1-TIP) were considered during
analysis.
Chemistry
Chemicals and solvents were purchased from Merck (Darmstadt,
Germany), Sigma-Aldrich and Fluka (Basel, Switzerland). All
reagents were of analytically pure. All solvents were dried by
standard methods and distilled before use. The sodium hydride
was used as a 60% dispersion in mineral oil. 18-Crown-6 ether
was prepared according to a literature procedure46. Reactions
were monitored on silica gel precoated TLC plates, HF254
(Merck). The dry-flash chromatography on silica gel (12–16 m,
ICN Pharmaceuticals, Costa Mesa, CA) was used to purify the
reaction products. Anhydrous reactions were carried out in oven-
dried glassware in extra pure argon atmosphere. 1H and 13C
NMR spectra were recorded on a Bruker Avance 500 (Bruker
BioSpin GmbH, Karlsruhe, Germany), or Varian (Palo Alto, CA)
Gemini 2000 instruments on 500/125 or 200/50 MHz, in CDCl3
with TMS as an internal reference. ESI-MS spectra were
recorded on Agilent Technologies (Santa Clara, CA) 6210-1210
TOF-LC-ESI-HR/MS instrument in positive mode. Integrity and
purity of all compounds used for biological tests are routinely
checked by NMR and ESI/HR-MS.
General procedure for the synthesis of compounds 1 and 2
1-Benzyl-piperidine-2,6-dione (1, C12H13NO2). Toluene (20 mL)
and sodium hydride (2.9 g, 72 mmol) were placed in a two-necked
flask equipped with reflux condenser and dropping funnel. A
solution of 4-benzylcarbamoyl-butyric acid methyl ester 1 c
(5.0 g, 18 mmol) in toluene (30 ml) was added and mixture
was refluxed for 3 h. After cooling at room temperature the
mixture was filtered and the filtrate was evaporated under reduced
pressure to give 65 % of compound 1 (C12H13NO2).
1H NMR
(200 MHz, CDCl3): ¼ 7.36–7.24 (m, 5H, Ar–H), 4.94 (s, 2H;
CH2), 2.65 (t, J¼ 6.5 Hz, 4H, CH2), 1.98–1.88 (m, 2H, CH2) ppm;
13C NMR(50 MHz, CDCl3): ¼ 172.5 (CCOimide), [137.3, 128.8,
128.4, 127.4 (CAr)], 42.6 (CCH2), 32.9 (CCH2), 17.0 (CCH) ppm;
HR-MS (ESI, m/z): calcd. for C12H13NO2 [M+ NH4]
+: 221.1284;
found: 221.1278.
8-Benzyl-8-aza-spiro[4.5]decane-7,9-dione (2, C16H19NO2).
Prepared from methyl ester 2e. Yield 75%; 1H NMR (200 MHz,
CDCl3): ¼ 7.37–7.24 (m, 5H, Ar–H), 4.94 (s, 2H, CH2), 2.60
(s, 4H, CH2), 1.72–1.65 (m, 4H, CH2), 1.50–1.44 (m, 4H, CH2)
ppm; 13C NMR (50 MHz, CDCl3): ¼ 172.1(CCOimide), [137.2,
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128.5, 128.3, 127.3 (CAr)], 44.7 (CCH2), 42.6 (CCH2), 39.4 (C),
37.4 (CCH2), 24.1 (CCH2) ppm; HR-MS (ESI, m/z): calcd. for
C16H19NO2 [M+ H]
+: 258.1489; found: 258.1480.
General procedure described in our previous paper was used for
preparation of compounds 3–9
2,6-Dioxo-1-phenethylpiperidine-3-carbonitrile (3, C14H14N2O2).
Yield 65%; 1H NMR (200 MHz, CDCl3): ¼ 7.34–7.19 (m, 5H,
Ar–H), 4.05 (splitted t, J¼ 7.0 Hz; J¼ 2.1 Hz, 2H, CH2), 3.71 (dd,
J¼ 9.3 Hz, J¼ 5.3 Hz, 1H, CH), 2.95–2.81 (m, 3H, CH2), 2.72–
2.56 (m, 1H, CH2), 2.36–2.17 (m, 2H, CH2) ppm;
13C NMR
(50 MHz, CDCl3,): ¼ 169.6 (CCOimide), [137.7, 129.0, 128.5,
126.7 (CAr)], 115.1 (CCN), 41.6 (CCH2), 35.7 (CCH2), 33.6
(CCH), 30.7 (CCH2), 21.5 (CCH2) ppm; HR-MS (ESI, m/z):
calcd. for C14H14N2O2 [M+ NH4]
+: 260.1393, found: 260.1389.30
Tert-pentyl-2,6-dioxo-1-phenethylpiperidine-3-carboxylate (4,
C19H25NO4). Yield 70%;
1H NMR (200 MHz, CDCl3) ¼ 7.30–
7.21 (m, 5H, Ar–H), 4.04–3.96 (m, 2H, CH2), 3.57–3.51 (m, 1H,
CH), 2.86–2.78 (m, 2H, CH2), 2.67 (dt, J¼ 11.6 Hz, J¼ 5.8 Hz,
2H, CH2), 2.25–2.07 (m, 2H, CH2), 1.80 (q, J¼ 7.5 Hz, 2H, CH2),
1.46 (s, 6H, CH3), 0.90 (t, J¼ 7.5 Hz, 3H, CH3) ppm; 13C NMR
(50 MHz, CDCl3): ¼ 171.3 (CCOimide), 168.8 (CCOimide), 167.7
(CCOester), [138.4, 128.9, 126.4 (CAr)], 85.6 (C), 50.0 (CCH),
41.1 (CCH2), 33.8 (CCH2), 33.3 (CCH2), 30.8 (CCH2), 30.2
(CCH2), 25.3 (CCH3), 20.7 (CCH2), 8.1 (CCH3) ppm; HR-MS
(ESI, m/z): calcd. for C19H25NO4 [M+ H]
+: 332.1856, found:
332.1841.
Tert-pentyl-1-benzyl-4-methyl-2,6-dioxopiperidine-3-carboxyl-
ate (5, C19H25NO4). Yield 46.6%;
1H NMR (200 MHz, CDCl3):
¼ 7.38–7.24 (m, 5H, Ar–H), 5.04–4.88 (m, 2H, CH2), 3.59
(d, J¼ 4.9 Hz, 0.13 H, CH), 3.21 (d, J¼ 9.0 Hz, 0.59 H, CH), 2.83
(dd, J¼ 16.5, J¼ 3.9 Hz, 1 H, CH), 2.74–2.68 (m, 0.41 H, CH2),
2.60–2.46 (m, 1H, CH2), 2.43–2.29 (m, 1H, CH2), 1.76
(dt, J¼ 9.4 Hz, J¼ 4.8 Hz, 2H, CH2), 1.44 (s, 5H, CH3), 1.36
(d, J¼ 3.5 Hz, 1H, CH3), 1.14–1.07 (m, 3H, CH3), 0.91–0.75 (m,
3H, CH3) ppm;
13C NMR (50 MHz, CDCl3): ¼ 170.9
(CCOimide), 169.1(CCOimide), 167.4 (CCOester), [136.9, 128.7,
128.4, 127.5 (CAr)], 85.4 (C), 57.9 (CCH), 43.0 (CCH2), 38.6
(CCH2), 33.4 (CCH2), 27.7 (CCH), 25.3 (CCH3), 25.2 (CCH2),
19.1 (CCH3), 8.1 (CCH3) ppm; HR-MS (ESI, m/z): calcd. for
C19H25NO4 [M+ NH4]
+: 349.2122, found: 349.2128.
1-((R)-1-Phenylethyl)-3-(phenylsulfonyl)piperidine-2,6-dione
(6, C19H19NO4S). Yield 68%;
1H NMR (200 MHz, CDCl3):
¼ 7.90–7.26 (m, 10H, Ar–H), 6.19–6.00 (m, 1H, CH), 4.13–
3.942 (m, 1H, CH), 3.44–3.14 (m, 1H, CH2), 2.92–2.71 (m, 2H,
CH2), 2.45–2.25 (m, 1H, CH2), 1.77–1.71 (m, 3H, CH3) ppm;
13C
NMR (50 MHz, CDCl3): ¼ 171.1 (CCOimide), 170.8 (CCOimide),
[139.6, 134.5, 134.4, 129.2, 129.0, 128.1, 128.0, 127.7, 127.0,
126.8 (CAr)], 66.2 (CCH), 50.3 (CCH), 50.1 (CCH), 29.8 (CCH2),
29.4 (CCH2), 17.6 (CCH3), 17.4, (CCH3), 15.8 (CCH2) ppm; HR-
MS (ESI, m/z): calcd. for C19H19NO4S [M+ H]
+: 358.1099,
found: 358.1108.
2-Benzyl-2-azaspiro[5.11]heptadecane-1,3,7-trione (7,
C23H31NO3). Yield 42.1%;
1H NMR (500 MHz, CDCl3):
¼ 7.34–7.23 (m, 5H, Ar–H), 4.95 (ABq, 2H, CH2,
J¼ 14.6 Hz), 3.23–3.17 (ddd, 1H, CH2, J¼ 7.6 Hz, J¼ 5.3 Hz,
J¼ 1.0 Hz), 2.68–2.56 (m, 2H, CH2), 2.59–2.53 (m, 2H, CH2),
2.00–1.95 (m, 1H, CH2), 1.60–1.47 (m, 4H, CH2), 1.33–1.19 (m,
15H, CH2), 0.96–0.89 (m, 1H, CH2) ppm;
13C NMR (125 MHz,
CDCl3): ¼ 204.8 (CCOketo), 172.7 (CCOimide), 171.9
(CCOimide), [136.9, 128.8, 128.4, 127.5 (CAr)], 60.0 (CCH),
43.4 (CCH2), 34.7 (CCH2), 33.9 (CCH2), 29.9 (CCH2), 26.3
(CCH2), 26.2 (CCH2), 23.3 (CCH2), 23.1 (CCH2), 22.0 (CCH2),
21.7 (CCH2), 18.8 (CCH2) ppm; HR-MS (ESI, m/z): calcd. for
C23H31NO3 [M+ H]
+: 370.2377, found: 370.2371.
2-Benzyl-2-azaspiro[5.7]tridecane-1,3,7-trione (8, C19H23NO3).
Yield 53%; 1H NMR (200 MHz, CDCl3): ¼ 7.28–7.23 (m, 5H,
Ar–H), 4.91 (s, 2H, CH2), 3.19–2.40 (m, 6H, CH2), 2.25 (ddd,
J¼ 12.3 Hz, J¼ 6.2 Hz, J¼ 3.4 Hz, 1H, CH2), 1.88–1.53 (m, 9H,
CH2) ppm;
13C NMR (50 MHz, CDCl3): ¼ 213.3 (CCOketo),
172.3 (CCOimide), 171.6 (CCOimide), [137.0, 128.4, 128.2, 127.3
(CAr)], 57.9 (C), 43.1 (CCH2), 38.3 (CCH2), 31.4 (CCH2), 30.0
(CCH2), 29.5 (CCH2), 25.7 (CCH2), 23.9 (CCH2), 23.8 (CCH2),
22.5 (CCH2) ppm; HR-MS (ESI, m/z): calcd. for C19H23NO3
[M+ H]+: 314.1751, found: 314.1738.
Ethyl 4-(1-benzyl-2,6-dioxopiperidin-3-yl)butanoate (9,
C18H23NO4). Yield 42%;
1H NMR (200 MHz, CDCl3):
¼ 7.37–7.22 (m, 5H, Ar–H), 4.94 (s, 2H, CH2), 4.13 (q,
J¼ 7.1 Hz, 2H, CH2), 2.82 (dt, J¼ 17.6 Hz, J¼ 4.9 Hz, 1H, CH2),
2.64 (dd, J¼ 11.1 Hz, J¼ 5.3 Hz, 1H, CH2), 2.54–2.42 (m, 1H,
CH), 2.34 (t, J¼ 7.2 Hz, 2H, CH2), 2.12–1.90 (m, 2H, CH2),
1.82–1.56 (m, 4H, CH2), 1.25 (t, J¼ 7.1 Hz, 3H, CH3) ppm; 13C
NMR (50 MHz, CDCl3): ¼ 174.5 (CCOimide), 173.2 (CCOester),
172.2 (CCOimide), [137.3, 128.5, 128.3, 127.3 (CAr)], 60.3
(CCH2), 42.9 (CCH2), 41.9 (CCH2), 33.9 (CCH2), 31.9 (CCH2),
29.6 (CCH2), 22.2 (CCH2), 22.0 (CCH2), 14.1 (CCH3) ppm;
HR-MS (ESI, m/z): calcd. for C18H23NO4 [M+ H]
+: 318.1700,
found: 318.1691.
8-Oxaspiro[4.5]decane-7,9-dione (2c) was prepared according to
a modified literature procedure47.
7,9-Dioxo-8-azaspiro[4.5]decane-6,10-dicarbonitrile (2a) and
2,20-cyclopentane-1,1-diyldi acetic acid (2b) were prepared by a
known literature procedure48. Methyl 5-chloro-5-oxopentanoate
(1b) and methyl [1-(2-chloro-2-oxoethyl)cyclopentyl] acetate (2d)
were prepared by a modification of a known literature
procedure49.
Methyl 5-(benzylamino)-5-oxopentanoate (1c) and methyl 2-(1-(2-
(benzylamino)-2-oxoethyl) cyclopentyl) acetate (2e) were pre-
pared according to a modified literature procedure50.
Methyl 2-methylbutan-2-yl propanedioate (3b) was prepared by a
literature procedure51. Methyl 2-(phenylsulfonyl)acetate (3c) was
prepared by a literature procedure52.
Acrylamides (4a, 4c, 4d) and (E)-N-benzylbut-2-enamide (4b)
were prepared according to a modified literature procedure50.
-Ketoesters (5a–c) were prepared by a modification of a
literature procedure53.
Results and discussion
Chemistry
Glutarimide derivatives, depicted in Figure 1, were synthesized
according to previously reported procedures of our30 or other
research groups. Compounds 1 and 2 were prepared according to
a modified literature procedure. Cyclization of amido-esters,
derived from corresponding glutaric acid anhydrides, in presence
of the base (NaH), was carried out by reflux in toluene (3 h),
yielding glutarimides 1 and 2 (Scheme 1). Amido-esters 1c and 2e
were prepared from 1a and 2c, respectively, by a modification of
standard methods47,49,50.
Compounds 3–9 were synthesized by tandem process described
in our previous paper30. The process involved a base-catalyzed
Michael addition of active methylene compounds to secondary
acrylamides or crotonamides, followed by intramolecular
N-acylation of the carboxamido group. Synthesis of derivatives
3–6 was performed by reacting methyl l,2-cyanoacetate (3a),
methyl t-pentyl malonate (3b) and methyl 2-(phenylsulfonyl)acet-
ate (3c) with N-substituted acryl- and crotonamides (4a–c), under
the reaction conditions (Scheme 2A). Yields of products were
42–72%. In the reaction of -keto esters, comprising 5, 8 and 12
member rings, 5a–c, with N-benzyl acrylamide, imides 9, 8 and 7,
respectively, were obtained (Scheme 2B).
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Scheme 2. Synthetic paths to obtain com-
pounds (A) 3–6; and (B) 7–9.
Scheme 1. Synthetic path to obtain com-
pounds 1 and 2.
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Antiproliferative activity
The cytotoxicity of compounds 1–9 was tested toward selected
human cancer cell lines: cervix adenocarcinoma HeLa, human
myelogenous leukemia K562 and human breast carcinoma MDA-
MB-453 cells. Cell survival was determined by MTT test, after
72 h of exposure to compounds31,32. IC50 values (Table 1) are
shown in molar concentrations, as the mean ± SD, determined
from three independent measurements.
IC50 was defined as the concentration of the compound
inhibiting cell survival by 50%, compared with a vehicle-treated
control cells. The most potent compound, 7, was also tested
toward MRC-5, normal lung fibroblast cells. Compounds 2, 4, 5–
8 and 9 exerted dose-dependent cytotoxicity toward malignant
cells, while compound 7 appeared as the most active. Compound
7 exerted humble selectivity, with IC50 toward normal cells
37 mM. The decrease in survival of target cells induced by
compound 7 is shown in Figure 2.
Antibacterial activity
Antibacterial activity of compounds 1, 2, 4–8 and 9 was examined
against selected foodborne pathogenic bacteria, Gram-positive
species S. aureus (ATCC 25923), E. faecalis (ATCC 29212), B.
cereus (ATCC 10876), L. monocytogenes (ATCC 19115) and
Gram-negative species P. aeruginosa (ATCC 27853), E. coli
(ATCC 25922), S. enteritidis (ATCC 13076), P. hauseri (ATCC
13315), S. sonnei (ATCC 29930), Y. enterocolitica (ATCC
27729), E. coli O157:H7 (ATCC 12900). A preliminary screen-
ing, done by a disc diffusion method, indicated the ability of
bacteria to produce visible growth in the presence of compounds
1, 2, 4–8 and 9. In most cases, Gram-negative bacteria were more
resistant to the tested compounds than Gram-positive bacteria
(Table 2). The diameters of the inhibition zones, determined by a
disk diffusion method, ranged from 6.4 to 14.6 mm, in the
presence of 200mg of compounds tested.
The Gram-positive bacteria B. cereus were the most sensitive
to compounds 4 and 9 (14.6 and 14.2 mm, respectively). Such
activity was comparable to the effect of commercial antibiotic
gentamicin (14.8 mm). Also, there was no statistically significant
difference between the susceptibility of B. cereus on commercial
antibiotic tetracycline (12.4 mm) and compounds 2, 7 and 8 (12.1,
12.9 and 12.4 mm, respectively). Among Gram-negative bacteria,
S. sonnei was the most sensitive to compounds 2, 4 and 6 (11.5,
10.4 and 10.2 mm, respectively), comparable to antibiotic tetra-
cycline (11.4 mm). Other compounds did not show significant
antimicrobial activity against tested bacteria in the applied
concentration. Compound 5 did not show any antimicrobial
effect on tested Gram-positive and Gram-negative bacteria.
Due to the fact that the disk diffusion method is not entirely
reliable in determining the antimicrobial properties, the broth
microdilution method, as a rapid and quantitative method
Table 2. Antibacterial activity of compounds 1, 2, 4, 6–8 and 9, determined by the disk diffusion method.
Diameter of inhibition zone (mm) including the initial diameter of the disk (6 mm)*
Bacterial strain 1 2 4 6 7 8 9 Gy Tz
S. aureus 8.2 ± 0.2f 11.3 ± 0.4d 13.3 ± 0.4c 8.5 ± 0.2f 12.6 ± 0.2c 12.9 ± 0.1c 9.8 ± 0.2e 18.2 ± 0.8b 29.9 ± 0.5a
E. faecalis 10.1 ± 0.5c 10.8 ± 0.2c 9.3 ± 0.2d 8.1 ± 0.3e 9.4 ± 0.5d 10.2 ± 0.4c 10.3 ± 0.2c 12.1 ± 0.7b 15.8 ± 0.5a
B. cereus 9.3 ± 0.0c 12.1 ± 0.9b 14.6 ± 0.3a 9.6 ± 0.5c 12.9 ± 0.0b 12.4 ± 0.2b 14.2 ± 0.1a 14.8 ± 0.2a 12.4 ± 0.3b
L. monocytogenes 9.2 ± 0.3e 12.1 ± 0.2b 8.3 ± 0.5f 8.1 ± 0.1f 10.1 ± 0.7d 10.5 ± 0.5d 11.6 ± 0.4c 12.6 ± 0.7b 15.2 ± 0.4a
P. aeruginosa –x 9.6 ± 0.4b 7.3 ± 0.3c 7.4 ± 0.4c 7.1 ± 0.3c 7.0 ± 0.2c 7.5 ± 0.5c 21.3 ± 0.4a 9.1 ± 0.2b
E. coli 8.3 ± 0.5c – 8.2 ± 0.5c 8.0 ± 0.6c – 7.7 ± 0.1c 7.9 ± 0.3c 22.9 ± 0.8a 11.4 ± 0.4b
S. enteritidis 7.9 ± 0.3d 8.3 ± 0.6d 9.1 ± 0.1c 7.1 ± 0.2e – – 6.8 ± 0.6e 25.3 ± 0.4a 22.5 ± 0.6b
P. hauseri – – 6.9 ± 0.3d 8.6 ± 0.6c 6.4 ± 0.7d 6.8 ± 0.3d – 25.6 ± 0.5a 24.8 ± 0.3b
S. sonnei 9.7 ± 0.6d 11.5 ± 0.8b 10.4 ± 0.3c 10.2 ± 0.2c 9.8 ± 0.1d 9.9 ± 0.4d 8.7 ± 0.0e 16.6 ± 0.4a 11.4 ± 0.4b
Y. enterocolitica 8.9 ± 0.0c 8.4 ± 0.6c 8.6 ± 0.2c 7.4 ± 0.3d 7.7 ± 0.2d 7.9 ± 0.3d 7.1 ± 0.4d 30.9 ± 0.4a 26.8 ± 0.8b
E. coli(0157:H7) 8.1 ± 0.7c – 7.6 ± 0.3c 7.8 ± 0.1c – – – 21.8 ± 0.6b 33.7 ± 0.1a
*Data are expressed as mean ± standard deviation (n¼ 3).
yG-gentamicin.
zT-tetracycline.
Within the same row, means followed by different letters are significantly different at p50.05 (ANOVA, Fisher’s LSD).
xInhibition zone not achieved.
Figure 2. Dose–response curves for the cytotoxicity of compound 7
toward HeLa, K562, MDA-MB-453 and MRC-5 cells. Percentage
of viable cells (S%) was plotted against various concentrations of
compound 7.
Table 1. Concentrations of compounds 1–9 that induced 50% decrease in
cell survival (IC50).
IC50 (mM)
Compound HeLa K562 MDA-MB-453 MRC5
1 4200 4200 4200 –
2 150.2 ± 2.0 103.9 ± 4.4 167.8 ± 3.8 –
3 4200 4200 4200 –
4 119.3 ± 1.3 96.6 ± 2.5 150.9 ± 0.2 –
5 108.4 ± 8.1 81.1 ± 0.8 135.7 ± 0.2 –
6 154.3 ± 6.9 147.1 ± 8.7 200 –
7 26.8 ± 4.7 8.98 ± 0.64 27.36 ± 0.20 36.73 ± 0.65
8 146.7 ± 5.9 150.0 ± 0.1 138.1 ± 3.5 –
9 186.5 ± 1.2 193.6 ± 6.4 195.2 ± 4.8 –
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for determining of MIC, based on the color change caused by
the enzymatic activity of viable microorganisms, was applied
(Table 3). Compounds 1, 2, 4, 6–8 and 9 inhibited the growth of
all tested Gram-positive and some of the Gram-negative bacteria.
Achieved MICs were in the range of 0.625–10.0 mg/mL
(1.97 103– 4.92 102 mol/L).
The highest antibacterial potential was reached with compound
9 against B. cereus (MIC was 0.625 mg/mL¼ 1.97 103 mol/L).
MICs against Gram-negative bacteria exceeded 10.0 mg/mL, for
the majority of compounds, including compound 5, proved to be
inactive in concentrations up to 10.0 mg/mL against all bacterial
strains tested. Exceptions were compound 4, whose antibacterial
activity ranged from 5.0 to 10.0 mg/mL against all tested Gram-
negative bacteria and compounds 2, 6 and 7, with MICs of
10.0 mg/mL (3.89 102, 2.80 102 and 2.71 102 mol/L,
respectively) against S. sonnei.
Structure–activity relationship
Although exerting humble potency, derivatives 9 and 4 appeared
most potent against bacteria, while derivative 7 was the one with
fair potency toward human tumor cells. In order to rationalize
structural features associated with the most potent compounds we
calculated molecular descriptors derived from the 3D structures of
compounds. For modeling studies structures of all compounds
(1–9) were prepared as described in our previous paper54, see
section ‘‘Methods’’. Due to low number of compounds tested
against bacteria, or toward human tumor cells, and limited
potencies, we did not build novel quantitative structure–activity
models, but envisaged to use molecular properties and to use
previously built model to draw conclusions on structural charac-
teristics needed for significant potency. To predict potency of
compound 7 toward K562 cells, we projected structures of
compounds 2, 7 and 8 (all spirocyclic compounds in our dataset)
on model previously derived for antiproliferative activity data of
glutarimide derivatives toward K562 cells, collected from
National Cancer Institute (NCI) repository54. Unfortunately, our
prediction failed. Compounds 2 and 7 were predicted as more
potent comparing to compound 8 (data not shown). There are
several possible reasons for the poor prediction. First, in the T
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Figure 3. Heatmap depiction of descriptors (auto- and cross-correlo-
grams), calculated by AMANDA algorithm, for compounds 1–9.
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model of antiproliferative activity of NCI glutarimides toward
K562 cells, potency data span range from 4 to 8.6 (p(GI50)
values). Approximating equality between p(IC50) and p(GI50)
values, which for sure is not the most stringent criteria;
compounds 2 and 7, with p(IC50) of 3.98 and 3.82, respectively,
are out of the range of potencies that NCI model covers. Next,
antiproliferative data of compounds tested by NCI were obtained
by Sulforhodamine B assay after 48 h of exposure of cells to
compounds, while we used MTT assay and exposed cells to
compounds during 72 h. The most potent compounds in NCI set
comprise unsubstituted glutarimide nitrogen, while all compounds
in our set bear bulky substituent in this position. Finally, our
model of antiproliferative activity of NCI glutarimides was built
on the pharmacophoric similarity patterns (including spatial
positions of HBA, HBD, hydrophobic and shape features), but did
not include whole-molecule properties, as surfaces and volumes.
Next, we compared whole-molecular properties of compounds 1–
9 (surface area, polar surface area, apolar surface area, volume,
virtual logP; Supplemental Information, Table S1) derived from
the 3D structures of compounds. We concluded that derivative 7,
most potent toward human tumor cells tested, had the largest
molecular volume. This observation is in accordance with the fact
that compounds having largest molecular volumes are among
most potent in NCI glutarimide set (Figure 4a in reference54). To
obtain more data on structural features associated with most
potent compounds in our set, we calculated MIF, with hydrogen-
bond donor (N1), hydrogen-bond acceptor (O), hydrophobic
(DRY) and shape (TIP) probes around compounds 1–9 in program
Pentacle, and visually inspected interaction patterns, obtained by
two-point pharmacophoric features offered by AMANDA algo-
rithm45,55. Blocks of correlograms were depicted as a heatmap
(Figure 3). Features that separate the most potent compounds
from the rest appeared straightforwardly.
We observed TIP-TIP and DRY-TIP blocks of variables which
were broader for compounds 4, 7 and 9, comparing with the same
block of variables for the rest of compounds. Along with this, the
N1-TIP block of variables is significantly broader for compound
9, compared to other compounds. So, variables in those three
blocks, with the largest distances between nodes, made distinction
between compounds 4, 7 and 9 and the rest. Variables TIP-TIP-
230, encoding nodes of shape probe on distance of 17.1 A˚
(Supplemental Information, Figure S19a), and DRY-TIP-408,
encoding node of hydrophobic probe and the node of shape probe
on distance of 17.4 A˚ (Supplemental Information, Figure S19b),
clearly separated compound 7, most potent toward tumor cells
tested, from the rest. Along the largest molecular volume,
compound 7 comprises bulky cycloalkyl moiety distal from the
benzyl ring bound to glutarimide N. We observed similar
structural features for compounds 9 and 4, most active against
Gram-positive bacteria. Variables TIP-TIP-233 (nodes of the
shape probe on distance of 18.1 A˚) and DRY-TIP-410 (node of
the hydrophobic probe on distance of 18.1 A˚ from the node of
shape probe) encoded compound 9. Variables TIP-TIP-234 (nodes
of the shape probe on distance of 18.4 A˚) and DRY-TIP-411
(node of the hydrophobic probe on distance of 18.4 A˚ from the
node of shape probe) encode compound 4. Along with those two
variables, comparable with variables associated with compound 7,
that described overall shape and spatial position of benzyl moiety
and branched alkyl chains attached to position 3 of glutarimide
ring in compounds 9 and 4; we observed additional variables
characteristic for compound 9. Variables N1-TIP-584 (HBD
associated with keto group in glutarimide ring, and alkyl moiety
of the ester, associated with the shape probe, on spatial distance of
17.1 A˚) and N1-N1-157 (HBDs associated with keto group in
glutarimide ring and with ester keto moiety) are typical for
compound 9. We did not observe similar variables for compound
4, most probably because ester keto group, as a HBA, was
hindered with branched alkyl moiety. All variables described for
compounds 9 and 4 are depicted in Figures S20 and S21
(Supplemental Information). So, along with overall large molecu-
lar volumes, due to alkyl chains bound to position 3 of
glutarimide moiety, compound 9, which exerted better antibac-
terial activity than the rest of compounds, has HBA moiety in this
alkyl chain and this HBA is not hindered by the vicinal parts of
molecule.
Conclusion
The cytotoxicity study of compounds 1–9 toward selected human
cancer cell lines showed that compound 7 was the most potent,
with IC50 values 8.98, 26.8 and 27.36 mM, toward K562, HeLa and
MDA-MB-453 cells, respectively. This compound exerted modest
selectivity toward normal control MRC-5 cells with IC50 37mM.
Preliminary screening of antibacterial activity by a disk diffusion
method showed that Gram-positive bacteria were more susceptible
to tested compounds than Gram-negative bacteria. Compounds 4
and 9 expressed the highest inhibition on growth of Gram-positive
bacteria B. cereus and it is comparable to antibiotic gentamicin.
S. sonnei (Gram-negative bacteria) was the most sensitive to the
compound 2 (comparable to antibiotic tetracycline). Using a
quantitative method for determination of MIC the highest
antibacterial potential was achieved with compound 9 against
B. cereus. Compound 5 did not show any antimicrobial effect on
tested Gram-positive and Gram-negative bacteria in any of applied
tests. Whole-molecular descriptors derived from 3D structures of
examined compounds and structure–activity model based on MIF,
calculated by the GRID method, rationalized structural features
associated with the most potent compounds. Compound with
bulky hydrophobic moiety distal from glutarimide ring exerted
best antiproliferative potency within studied set.
We found that compound 7 exerts the highest antiproliferative
potency within studied set. This derivative will be a starting point
for further structural modifications in order to obtain more potent
compounds. As compound 7 exerts modest selectivity, the second
goal of structural modifications will be improvement of select-
ivity of new derivatives.
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